Janux Therapeutics (JANX) Company Report

JANX007 demonstrated a median radiographic progression-free survival (RPFS) of 7.9 months (QW) and 8.9 months (Q2W), alongside early and deep PSA reductions.
A new CRS mitigation protocol (CRS P2) resulted in primarily grade 1 CRS with resolution typically within 24 hours, supporting potential outpatient treatment. The company is prioritizing 6 mg and 9 mg target doses and a patient-friendly Q2W dosing schedule, which reduced grade 3 adverse events from 35% to 21%.
Janux Therapeutics is strategically focusing on taxane-naive, pre-Pluvicto MCRPC patients and exploring the PARP inhibitor refractory patient population, a market estimated at over $500 million and growing, which may offer an expedited approval pathway.
The company highlights that T-cell engagers, like JANX007, may show an outsized improvement in overall survival relative to RPFS, a key factor for prostate cancer approvals, with low tumor burden patients showing an improved RPFS of 10.5 months.

3 days ago

Janux Provides Interim Clinical Data for JANX007 Program

JANX

New Projects/Investments

Guidance Update

Janux presented interim Phase 1 clinical data for JANX007, a first-in-class, tumor-activated T-cell engager targeting PSMA for prostate cancer.
The data showed durable responses and a median radiographic progression-free survival (RPFS) of 7.9 months in an expanded group of 29 patients, with a manageable safety profile.
An every-other-week (Q2W) dosing schedule demonstrated an RPFS of 8.9 months in 19 evaluable patients and is supported for future development.
JANX007 showed improved efficacy in lower tumor burden patients, guiding the company's focus on early-line taxane-naive patient populations.
The company estimates the market size for PARP inhibitor refractory prostate cancer, a potential expedited approval path, to be over $500 million and growing.

3 days ago

Janux Therapeutics Reports Positive Data for JANX007 in MCRPC Patients

JANX

New Projects/Investments

Guidance Update

Janux Therapeutics has dosed over 100 patients in its phase Ia study for JANX007, reporting a median radiographic progression-free survival (RPFS) of 7.3 months for all subjects and 7.9 months for an expanded group of 29 patients.
The company's JANX007 program shows a maintained RPFS of 8.9 months for patients on an every-other-week (Q2W) dosing schedule, which also demonstrated a reduction in grade 3 adverse event profiles from 35% to 21% compared to once-weekly dosing, supporting a patient-friendly Q2W schedule.
Early phase Ib data in taxane-naive patients demonstrated rapid and deep PSA reductions with primarily grade 1 Cytokine Release Syndrome (CRS), suggesting potential for an outpatient treatment setting and an improved RPFS of 10.5 months in low tumor burden patients.
Janux Therapeutics is prioritizing 6 mg and 9 mg target doses and focusing on taxane-naive pre-Pluvicto MCRPC patients and PARP inhibitor refractory patients, with the latter market estimated at over $500 million and growing.

3 days ago

Janux Therapeutics Reports Third Quarter 2025 Financial Results and Business Highlights

JANX

Earnings

New Projects/Investments

Janux Therapeutics reported $989.0 million in cash, cash equivalents, and short-term investments as of September 30, 2025.
For the third quarter ended September 30, 2025, the company incurred $34.6 million in research and development expenses and $10.6 million in general and administrative expenses, resulting in a net loss of $24.3 million.
Enrollment is ongoing for the JANX007 and JANX008 clinical trials, with updates expected in the fourth quarter of 2025.

Nov 6, 2025, 9:10 PM

Earnings Transcripts

Quarterly earnings call transcripts for Janux Therapeutics.

Get instant answers from SEC filings, earnings calls & more

Get instant analysis when filings drop